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Abstract The management of patients with pancreatic
cancer has advanced over the last few years. We convey a
multidisciplinary group of experts in an attempt to stablish
practical guidelines for the diagnoses, staging and man-
agement of these patients. This paper summarizes the main
conclusions of the working group. Patients with suspected
pancreatic ductal adenocarcinoma should be rapidly eval-
uated and referred to high-volume centers. Multidisci-
plinary supervision is critical for proper diagnoses, staging
and to frame a treatment plan. Surgical resection together
with chemotherapy offers the highest chance for cure in
early stage disease. Patients with advanced disease should
be classified in treatment groups to guide systemic treat-
ment. New chemotherapeutic regimens have resulted in
improved survival. Symptomatic management is critical in
this disease. Enrollment in a clinical trial is, in general,
recommended.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC), the most com-
mon form of pancreatic cancer, currently stands as the third
most common cause of cancer related deaths [1]. In 2008 a
total of 70,000 of were diagnosed in Europe [2, 3]. Rates of
new cases of pancreatic cancer have increased on average
0.8% annually over the last ten years. The current 5- and
10-year survival rates at 7.2% and below 4%, respectively [4].
The aim of the present consensus guidelines is to pro-
vide a general overview of the diagnosis, a more global
patient´s classification, not just based on performance sta-
tus, treatment, and management of associated complica-
tions of patients with PDAC. These guidelines are the
result of expert consensus meetings that took place during
the months of September to December 2015 sponsored by
Fundacio´n ECO, where a total of forty-two medical
oncologists, radiotherapists, surgeons, radiologists,
pathologists, endocrinologists, gastrointestinal specialists
and palliative care specialists shared their opinions. These
recommendations are based on the results of clinical trials,
retrospective, observational studies, as well as the group of
experts´ opinion (levels of evidence: quality of evidence: I–
III; strength of recommendation: A–E) [5].
PDAC: signs and symptoms
The absence of specific manifestations, together with its
biological aggressiveness, results in delayed diagnosis in
more than 80% of cases. The most common symptoms
include fatigue, anorexia, weight loss, abdominal pain and
dark urine [6]. Sixty to 70% of tumors originate in the pan-
creatic head, 20–25% in the body and tail and in 10–20%
there is a diffuse involvement of the gland [7]. While tumors
in the pancreatic head tend to be diagnosed at earlier stages
because of the jaundice associatedwith bile duct obstruction,
tumors in the body and tail are usually detected in advanced
stages. Tumor with obstructive jaundice may be associated
with palpable gallbladder (Courvoisier sign). Head tumors
may also be associated with steatorrhea as a consequence of
exocrine pancreatic insufficiency and obstruction of the
pancreatic duct. Although with low specificity, the combi-
nation of diabetes mellitus (DM) of recent onset associated
with weight loss should lead to suspicion PDAC [8]. About
one in 125 (0.85%) patients with new-onset DM presents
PDAC, eight times more than expected, compared to the
general population [9]. Patients with newly diagnosed DM
without metabolic syndrome and difficult glycemic control
should be evaluated to rule out PDAC [10] (IIB). Special
attention should be paid to patients that present the following
symptoms: weight loss, abdominal pain, DM of recent onset
orwith poor disease control. Patientswith advanced stages of
PDAC may have epigastric palpable mass, hepatomegaly
secondary to liver metastases, ascites caused by peritoneal
carcinomatosis, pain, vascular and nerve infiltration and/or
gastric outlet obstruction. The PDAC is associated with
arterial and venous (hypercoagulable state) thrombosis such
as Trousseau syndrome (migratory superficial vein throm-
bosis. PDAC may also be associated with palpable supra-
clavicular lymph nodes (Virchow), anterior axillary (Irish)
or periumbilical mass (Sister Mary Joseph).
Familial PDAC and hereditary PDAC
The International Cancer of the Pancreas Consortium
Screening (CAPS) recommends screening of PDAC in
high-risk individuals (HRI) or families with familial pan-
creatic cancer (FPC), although this is not yet included in
routine clinical practice [11] (IIIC). PDAC screening pro-
grams should be performed in high-volume centers that
have multidisciplinary teams with experience in the
screening and treatment of the disease. HRI are considered
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as those who have at least 5–10 times increased risk of
PDAC [11] and include families with at least two first-
degree relatives affected, or C3 individuals regardless of
the degree of kinship. In addition, subjects with Peutz–
Jeghers syndrome, hereditary pancreatitis, or those affected
by other hereditary cancer syndromes (germline mutations
in the BRCA genes, familial melanoma or colorectal can-
cer hereditary) with a case of PDAC in the family [12].
The best screening techniques for HRI is magnetic res-
onance imaging (MRI) with magnetic resonance cholan-
giopancreatography (MRCP) and upper gastrointestinal
endoscopic ultrasound (EUS) [11–15] (Algorithm 1).
Pancreas with normal appearance Morphological altered pancreas
Confirmaon of absence of pancreac alteraons         
*Annual periodicity (IIIB)
**MRI and not biphasic TC is recommended to avoid radiaon to the paent
Abbreviaons: EUS: Endoscopic ultrasound; MRI: Magnec resonance imaging; FNA: Fine needle aspiraon (FNA)
When to refer to familial cancer consultaon for PDAC study:
• Families with FPC (≥ 2 first-degree relaves with PDAC or ≥3 with PDAC, regardless of their 
degree of kinship).
• Personal history of PDAC with personal or family history of other cancers associated with 
BRCA1 and BRCA2 hereditary colorectal cancer (familial adenomatous polyposis or Lynch 
syndrome) genes, or familial melanoma. 
• Suspicion of other hereditary syndromes: Peutz-Jeghers syndrome or hereditary pancreas.
EUS + MRI
Muldisciplinary CommieeMaintain screening periodicity*
Repeat EUS ± MRI or EUS-FNA Pancreac surgery 
Confirmaon of presence of 
pancreac alteraons
Algorithm 1. Screening algorithm of PDAC in high risk indviduals (IIIC)
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Screening tests aim to detect small pancreatic solid tumors
(B1 cm), irregular pancreatic duct, and pancreatic precur-
sor lesions such as intraductal papillary mucinous neo-
plasm (IPMN), which are usually present as cysts [16]. The
prevalence of suspected cystic pancreatic lesions is
33–45% in HRI [11, 15]. The CAPS recommend starting
screening at age 50 years, or ten years before the age of the
youngest case in the family [11] with annual exams if no
pancreatic lesions are observed [11] (IIIB). These intervals
could be modified at the discretion of the multidisciplinary
tumor committee. If suspicious abnormalities are detected,
surgery is indicated although the current available evidence
is limited [11–16].
Diagnosis
In patients with suspected PDAC based on medical history
and/or physical exam, the primary diagnostic approach to
the patient with PDAC is radiological. An abdominal
ultrasound is often the first test performed in patients with
abdominal pain and/or jaundice. US can detect dilatation of
the bile duct or pancreatic duct and the presence of a
pancreatic mass. However, the sensitivity for detecting
pancreatic tumors is low and ranges between 50 and 70%
[17]. Computer tomography (CT) scan is the gold standard
technique in the evaluation of patients with suspected
PDAC (IIA). The study of a pancreatic mass must include a
biphasic CT performed with an arterial phase (40–50 s)
and portal venous phase (65–70 s) [7, 17–19]. In most
cases, PDAC is seen in the arterial phase as a hypodense
pancreatic lesion, with poorly defined margins [7]. Fur-
thermore, CT scan detects the vascular involvement (arte-
rial and venous), extra-pancreatic local extension, presence
of lymph nodes, and detection of liver or peritoneal nod-
ules [7]. The availability of a high-quality multidetector CT
(preferably C16 detectors) combined with experience in
the interpretation of these studies has shown a more
accurate preoperative staging and better patients´ manage-
ment [18]. Magnetic resonance imaging (MRI) has equal
sensitivity and specificity than CT for staging PDAC, but
its use is not widespread because of its high cost and
reduced availability and is usually reserved for difficult
cases, cystic neoplasms of the pancreas and to explore
biliary anatomy as well [18]. Radiology report should
follow a standard format [18, 19].
Upper gastrointestinal endoscopy is useful to take
biopsies of tumors infiltrating the duodenum as well as for
palliative decompression of the duodenum and/or bile duct
[7]. Endoscopic retrograde cholangiopancreatography
(ERCP) is restricted to cases with obstruction of the bile
duct because is associated with significant adverse effects
and has low profitability of achieving a histological
diagnosis (20%) [7]. Endoscopic ultrasound (EUS) is an
important complementary examination in the diagnosis and
staging of PDAC as it permits examining the primary
tumors, relationship with neighboring structures as well as
obtaining tissue for pathological diagnoses [19]. The sen-
sitivity and specificity of EUS-guided tumor fine needle
aspiration (FNA) are 90 and 98%, respectively [20]. It
should be noted, however, that patients with clinical and
radiological suspected PDAC with resectable do not need a
pathological diagnoses before surgical resection (IIIB).
Pathological diagnoses are needed in patients with atypical
presentation and in those with locally advanced disease that
are managed with chemotherapy and/or radiation therapy
(IIIB).
Pathological diagnoses and classification
In the presence of suspicious lesions that are resectable, a
tumor biopsy prior surgery is not required. Likewise,
because of the complexity to obtain it as well as the lim-
itations on its interpretation an intraoperative biopsy is not
required [7, 21] (IIIB). A pathological diagnosis is always
required in patients with unresectable or borderline lesions
to be managed with chemotherapy and/or radiation therapy
as well as in patients with amenable to treatment with
metastatic disease [21] (IIIB).
The technique of choice to obtain tissue for pathological
diagnoses depends on the location of the lesion and the
stage of the disease. For primary tumors, a EUS-FNA is the
safest procedure with highest sensitivity and specificity that
can also provide additional staging information [22]. In
patients with metastatic liver disease, a percutaneous US-
or CT-guided biopsy is the procedure of choice [7, 21]
(IIIB). If a biopsy does not confirm malignancy, it should
be repeated atleast once. If during surgery the tumor is
unresectable, histological diagnosis should be made (IIIB).
Table 1 summarizes the histopathologic classification of
PDAC tumors. The most common type (95%) is ductal ade-
nocarcinoma of the pancreas, referred to as pancreatic cancer.
These tumors originate in ductal epithelium, have glandular
differentiation, may produce mucin, and are associated with a
significant desmoplastic reaction. There are no specific diag-
nostic markers to differentiate PDAC from other adenocar-
cinomas though reactive glands, a CK7?/CK20- profile,
while not specific, supports a pancreatic origin.
Biomarkers
Although many biomarkers have been studied for PDAC,
only carbohydrate antigen 19.9 (CA 19.9) has proven
useful and therefore, it is the only biomarker routinely used
670 Clin Transl Oncol (2017) 19:667–681
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[23] (IA). For diagnoses, it has a sensitivity ranging
between 70 and 92% and a specificity of 68–92%
depending on tumor size. False positive results are asso-
ciated with benign diseases such as pancreatitis, cirrhosis,
acute cholangitis, and other diseases causing of cholestasis.
Determining CA 19.9 is a complementary test in the
diagnoses and management of PDAC [24]. In patients with
resectable disease, plasma levels[100 U/mL values pre-
dict the presence of occult metastatic disease. In advanced
disease, elevated CA 19.9 is considered as unfavorable
prognostic factor [25, 26]. However, given its low positive
predictive value, particularly in asymptomatic individuals,
is not recommended as a screening marker [27].
Timeline for diagnosis and management
Because PDAC is very aggressive, it is recommended to
reduce the diagnostic time as much as possible to rapidly
initiate treatment [28]. In a study in patients with advanced
PDAC it was estimated that the average doubling time of
pancreatic tumor was 40–60 days [29]. A month from the
onset of the first symptoms or suspicious signs is a rea-
sonable goal (IIIB).
The National Cancer Strategy Health System (2010)
states that the time from therapeutic decision until the
actual start of treatment should be less than 2 weeks for
surgical treatment, one week for chemotherapy and
4 weeks (including treatment planning) for radiation ther-
apy [30] (IIIB). Strategies to minimize time to diagnoses
include raising awareness in the general population and
among health professionals, rapid diagnostic protocols for
patients with suspected lesion in primary care settings as
well as preferential referral pathways to specialize care and
treatment centers. PDAC, like any other complex tumor,
should be managed in high referral centers by multidisci-
plinary teams: Medical oncologists, pathologists, radio-
therapist, GI specialist, surgeons and radiologists [30]
(IIIB).
Staging and disease classification
Pancreatic cancer can be staged, based on imaging and
pathological studies, in stages as per the TNM classifica-
tion [31, 32]. However, from a management perspective,
patients are better classified based on the extension of
disease in resectable, borderline resectable, locally
advanced unresectable and metastatic (IIIA).
In addition, from a treatment perspective, patients with
locally advanced/metastatic disease are further classified
as: (a) candidate to chemotherapy treatment without limi-
tations; (b) candidate for chemotherapy with limitations
Table 1 Pathological diagnosis
Classification of pancreatic tumors (WHO 2010 classification)
Benign
Acinar cell cystadenoma
Serous cystadenoma
Premalignant lesions
Pancreatic intraepithelial neoplasia type 3 (PanIN-3)
Intraductal papillary mucinous neoplasm with low or intermediate
grade dysplasia
Intraductal papillary mucinous neoplasms
High-grade dysplasia
Tubulo-papillary intraductal neoplasia
Mucinous cystic dysplasia neoplasia with low or intermediate
grade
Mucinous cystic neoplasm with high-grade dysplasia
Malignant
Ductal adenocarcinoma
Adenosquamous carcinoma
Colloid carcinoma (non-cystic mucinous carcinoma)
Hepatoid carcinoma
Medullary carcinoma
Cell carcinoma signet ring
Undifferentiated carcinoma
Undifferentiated carcinoma with osteoclast-like giant cells
Acinar cell carcinoma
Cystoadenocarcinoma acinar cells
Intraductal papillary mucinous neoplasm or associated with
invasive carcinoma
Mixed acinar-ductal carcinoma
Mixed acinar-neuroendocrine carcinoma
Mixed-neuroendocrine carcinoma acinar-ductal
Mixed ductal-neuroendocrine carcinoma
Mucinous cystic neoplasm associated with invasive carcinoma
Pancreatoblastoma
Serous cystoadenocarcinoma
Pseudopapillary or solid neoplasia
Neuroendocrine neoplasms
Pancreatic neuroendocrine microadenoma
Neuroendocrine tumor (NET)
Pancreatic, not functioning G1, G2 NET
G1 NET
G2 NET
Neuroendocrine carcinoma (NEC)
Large cell NEC
Small cell NEC
NET serotonin producer (carcinoid)
Gastrinoma
Glucagonoma
Insulinoma
Somatostatinoma
VIPoma
Mature teratoma
Mesenchymal tumors
Lymphomas
Metastasis
Clin Transl Oncol (2017) 19:667–681 671
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and (c) not candidate for treatment with chemotherapy
(Table 2) [6, 33–37] (IIIB).
Practical considerations in treatment decision
process
The treatment plans for patients with PDAC patients
should be made individually. A complete staging process is
essential to determine the extent of the tumor that drives
treatment plan and prognosis. In parallel, patient´s status,
which is linked to its ability to tolerate an aggressive
treatment, should be defined. This includes the functional
status as determine by the Karnofsky Performance Scale
(KPS) and/or the Eastern Cooperative Oncology Group
(ECOG). Patients with KPS of less than 60–70% or ECOG
less than 0–1 are limited to receive aggressive
chemotherapy. For elderly patients, it is also advisable to
use geriatric scales such as the Barthel scale that assesses
the degree of autonomy in basic activities of daily living
[37]. The assessment of nutritional status as measured by
physical exam (weight, body mass index, presence of
edema), recent weight lost ([10% over 6 months); plasma
protein levels (albumin, prealbumin, transferrin) is crucial
[38]. Validated nutritional scales such as Mini Nutritional
Assessment are useful in this regard. In addition, a life
expectancy of[3 months is usually needed to administer
cancer treatment. Mechanical problems caused by tumor
masses such as bile duct and bowel obstruction need to be
assessed and corrected prior to treatment commencement.
Finally, patient priorities and preferences need to be con-
sidered (IIIA).
Treatment approaches
Resectable disease/borderline resectable disease
Neoadjuvant treatment
Neoadjuvant treatment, which is the treatment with
chemotherapy and/or radiotherapy administered before surgi-
cal resections, aims to increase overall survival by increasing
the rate of R0 resection and early treatment of micrometastatic
Table 2 Patients’ classification, according to treatment perspective (IIIB)
Patients’ classification Factors
Patient suitable for chemotherapy treatment
without limitations
The presence of ALL the following factors
ECOG 0–1
Age B75 years
Bilirubin B1.5 ULN
Good nutritional status (serum albumin[2.5 mg/dl, weight lost\10% over the last 3–6 months
and BMI[20 kg/m2)
Lack of co-morbidities
Patient suitable for chemotherapy with
limitations
The presence of AT LEAST ONE of the following factors
ECOG 2 (which can lead to KPS 70%)
Age[75 years
Mild to moderate neurological or endocrine-metabolic organ dysfunction; in case of liver
dysfunction, hyperbilirubinemia[1.5 9 ULN (once optimized if obstructive causes are present,
for example with biliary stent) marks the degree of dysfunction. It is considered appropriate to
adjust the dose, for example, using GEM at 600-800 mg/m2 and nab paclitaxel 75–100 mg/m2)
[37]
Cardiac dysfunction, especially a recent ischemic event; acute, symptomatic, severe TED such as
PE with hemodynamic instability or DVT with risk and limb amputation [38]
BMI\20 kg/m2 or[10% weight loss in 3–6 months
Patient not suitable for chemotherapy
treatment
The presence of AT LEAST ONE of the following factors
ECOG 3-4 (which may result in KPS B 60%). Active treatment will be initiated in patients with
ECOG 3 secondary to the disease (not to their previous comorbidities) without any severe organ
dysfunction, thus moving this subgroup of patients to the ‘‘candidate for chemotherapy treatment
with limitations’’ group
Severe organ dysfunction: neurological (e.g., severe cognitive impairment, Alzheimer’s type);
endocrine-metabolic, infectious (uncontrolled HIV), renal, hepatic dysfunctions, etc
ECOG Eastern Cooperative Oncology Group, ULN upper normal limit, BMI body mass index, GEM gemcitabine, KPS Karnofsky performance
status, TED thromboembolic disease, PE pulmonary embolism, DVT deep venous thrombosis
672 Clin Transl Oncol (2017) 19:667–681
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disease. In addition, preoperative treatment may lead to
avoiding unnecessary surgical resection in patients with
aggressive tumors that develop early progression.
It should be noted, however, that there are no random-
ized phase 3 studies to support any of these assumptions.
Prior studies suggest an increment in the rate of R0
resections [39–41]. Most studies reported thus far were
conducted with old, less effective chemotherapy regiments
and the data available with modern regimens [gemcitabine
(GEM)/nab paclitaxel, FOLFIRINOX], came from single-
center trials [35, 42–47].
Here, we discuss preoperative management of patients
with resectable or borderline resectable disease. Prior to
treatment initiation, it is important to have pathological
diagnosis as well as normalized bile duct drainage. Endo-
scopically placement of a metal stent is the procedure of
choice to palliate obstructive jaundice (IIIB).
For patients with resectable disease neoadjuvant treat-
ment cannot be recommended outside a clinical trial.
However, preoperative treatment is one of the available
approaches in patients with borderline resectable disease
(IIB). The chemotherapy treatments used should be those
associated with higher response rate in patients with
metastatic disease (GEM/nab paclitaxel, FOLFIRINOX)
[35, 46] (IIB). Currently there is no evidence to recom-
mend one versus the other and the decision should be based
on patients´ characteristics and center experience. In gen-
eral, treatment should be administered for 3–4 months with
a reassessment and multidisciplinary discussion afterwards
(IIB). Patients with responding tumors by either radiolog-
ical criteria or CA 19.9 could proceed to surgical resection
[48, 49] (IIB). Radiotherapy the alone is not recommended
and should be combined with either fluoropyrimidines or
GEM (IIB). IMRT is associated with reduced toxicity and
should be used when available. Patients who receive
chemo-radiation should wait four to eight weeks before
attempting surgical resection (IIB).
Radiological evaluation must be conducted after
neoadjuvant treatment. Lack of objective radiological
response should not be a criterion to rule out surgical
resection [52] (IIB). Those patients with suspected disease
progression by either elevated CA 19.9 without radiologi-
cal evidence of disease progression should be carefully
evaluated and PET scan and laparoscopy should be con-
sidered (IIB). Patients with documented metastatic pro-
gression are not candidates for surgery and should be
managed as such (IIB).
Surgical treatment
An R0 surgical resection is the only curative treatment for
patients with pancreas cancer and should always be
attempted. Prior to considering surgery, patients need to be
assessed by a multidisciplinary team and classified as
resectable, borderline resectable or unresectable locally
advanced being the multidetector CT scan the radiological
procedure of choice for this matter [18, 50] (IIA). Based on
the extent of the tumor, involvement of blood vessels
[portal vein, superior mesenteric vein (SMV); superior
mesenteric artery (SMA); celiac trunk and hepatic artery]
patients are classified in one of the above-mentioned group
[31, 51–55]. Table 3 provides the specific criteria [57].
More recent classifications also include changes induced
by preoperative treatments. It should be noted that exten-
sion to adjacent organs, if resectable, is not a contraindi-
cation for surgery.
In addition to stage classifications, a complete assess-
ment of operative risk should be performed. Considering
the high morbimortality of pancreatic cancer resection, its
assessment is of great importance. Classic surgical risk
scales, such as Apache, ASA and POSSUM, do not predict
accurately the morbidity after pancreatic surgery. Other
more recent classification such as the one published by
Braga, as well as the Preoperative Pancreatic Resection
(PREPARE) and SOAR (Surgical Outcomes Analysis and
Research) scores are based on the integration of multiple
parameters and appear more accurate [56–59].
Prior to surgical resection, it is critical to gain an ade-
quate nutritional status and either nutritional supplements
or even parenteral nutrition should be considered for
1–2 weeks prior to surgery in malnourished patients. In
patients with large tumors, particularly of the tail of the
pancreas, borderline resection and high tumor marker, a
diagnostic laparoscopy should be considered prior to
laparotomy.
For patients with tumors in the head of the pancreas, the
procedure of choice is the duodenal pancreatectomy
(Whipple procedure), which includes en bloc resection of
the head of the pancreas, duodenum, gall bladder and bile
duct, together with regional lymphadenectomy [57] (IA).
Pylorus preserving pancreatectomy is equivalent to classic
Whipple with regards to morbimortality and outcome and
the selection of surgery type depends on surgeon prefer-
ence. Other procedures such as extended pancreatectomy,
total pancreatectomy, and extended lymphadenectomy are
reserved for selected cases [60, 61].
Patients with tumors of the body or tail of the pancreas
are treated with distal pancreatectomy.
As mentioned above, laparoscopy can detect small
peritoneal implants or liver metastasis not visible by CT
scan and is often used in patients with high risk of meta-
static disease [62] (IIB). In addition, for patients with
tumors in the body and tail of the pan, laparoscopy
resection with or without robot assistance, is gaining
acceptance [63]. Finally, vascular involvement has been
traditionally considered a formal contraindication for
Clin Transl Oncol (2017) 19:667–681 673
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resection [64, 65]. More recently, however, venous resec-
tion and reconstruction is accepted as an optimal surgical
procedure and is not associated with worse prognosis.
However, arterial resection and reconstruction is still
considered an investigational approach [51, 57, 65].
Adjuvant treatment
Adjuvant treatment is recommended in patients who
undergo an R0/R1 resection with a PT1-4/N0-1M0, with an
ECOG PS 0–1 and proper nutritional status [66, 67].
Treatment of patients with ECOG 2 needs to be individu-
alized [66, 67].
It is recommended that adjuvant treatment is initiated
within the next 12 weeks after surgery in patients who do
not have any active infection, any serious postsurgical
complication or presents with signs or symptoms of
recurrent disease. There is no consensus on the adjuvant
treatment in patients who have received neoadjuvant
treatment [7, 68–70]. Those patients need to be evaluated
in a multidisciplinary board. In general, adjuvant treatment
in this population is still considered investigational. As a
general rule, patients who have received neoadjuvant
treatment should receive adjuvant treatment to complete a
total of six months of treatment (IIIB).
With regards to the role of radiation therapy, there is
even less information and could be considered in those
patients with positive margin providing was not adminis-
tered in the preoperative period (IIC). Prior to adjuvant
chemotherapy commencement patient needs to be evalu-
ated with a CBC, chemistry, renal function test, albumin,
LDH and CA 19.9 levels [7, 71–73]. A CT of the chest,
abdomen and pelvis is required to document lack of disease
progression [18, 71, 73]. Currently, and until the results of
ongoing studies are available, the recommended treatment
is single agent GEM, or 5-FU and leucovorin (LV), for a
total of six months [66, 67, 74–76] (IA). The results of the
recent clinical trial ESPAC-4 support the use of
GEM ? capecitabine in this setting [76] (IA). The role of
radiation therapy is less defined and should be considered
for patients with positive margins and in selected cases
with lymph node positive disease [75–82] (IC).
Table 3 Resectability criteria [57]
Category Arterial Venous
Resectable Absence of tumoral contact with CT, MSA or CHA Absence of tumoral contact with SMV or PV or contact B180
without irregularities in the venous contour
Borderline
resectable
Head of the pancreas and uncinate process
Solid tumoral contact with CHA, without extension to CT or
HA bifurcation, that allows resection and complete and safe
vascular reconstruction
Solid tumoral contact with SMA B180
The presence of arterial anatomic variants should be evaluated
(i.e., right accessory HA, replacement of right HA,
replacement of CHA as well as source of replaced or
accessory artery) and the presence and degree of tumoral
contact due to their influence when planning the surgical
procedure
Body and tail of the pancreas
Solid tumoral contact with CT B 180
Solid tumoral contact with CT[ 180 without aorta
involvement and with intact GDA (there is no consensus on
this criteria and can be included in the non-
resectable category)
Solid tumoral contact with SMV or PV[180, contact B180
with irregularities in the venous contour or venous thrombosis
but with adequate proximal and distal ends that allow safe
vascular resection and replacement
Solid tumor contact with IVC
Non-
resectable
Distant metastasis (including metastasis in non-regional lymph
nodes)
Head of the pancreas and uncinate process
Solid tumoral contact with SMA or CT[180
Solid tumoral contact with the first jejunal branch of SMA
Body and tail of the pancreas
Solid tumoral contact with SMA or CTC[ 180
Solid tumoral contact with CT and aortic infiltration
Head of the pancreas and uncinate process
Tumoral infiltration or thrombosis (thrombosis may not be
tumoral) in SMV or PV, that does not allow reconstruction
Contact with the most proximal jejunal vein that drains in SMV
Body and tail of the pancreas
Tumoral infiltration or thrombosis (the thrombosis may not be
tumoral) in SMV or PV, that does not allow reconstruction
CT celiac trunk, SMA superior mesenteric artery, CHA common hepatic artery, SMV superior mesenteric vein, PV portal vein, IVC inferior vena
cava inferior, GDA gastroduodenal artery
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Those patients with positive margins and neoadjuvant
treatment that did not include radiation therapy are a par-
ticularly suitable group for postoperative radiotherapy.
Currently, there is no biomarker predictive of outcome in
this patient population and CA 19.9 is the only prognostic
indicator [83]. Once treatment is completed, patient should
be followed every three months with measurement of CA
19.9 levels and a physical exam [7, 83–85] (IIIB). A CT
scan should be performed every 6 months during the first
2–3 years after surgery and yearly thereafter [7, 83–85].
Unresectable disease
Management of patients with locally advanced disease
The management of patients with locally advanced disease
is one of the most controversial areas in the treatment of
PDAC due to the paucity of well controlled, randomized
clinical trials. The goal in treating these patients is to
improve survival which is better achieved if a complete
surgical resection is feasible. Patients with locally
advanced disease need to be evaluated like any other
patient with PDAC with special attention to nutritional
status, ECOG performance status, symptoms related to
tumor local growth (pain, bowel and/or bile duct obstruc-
tion). The presence of bile duct or bowel obstruction need
to be corrected before treatment is initiated. For patients
who are candidates of chemotherapy treatment without
limitations, this is in general the recommended approach
(Table 2). While there are no data with regards to the most
efficient regimen in this particular setting, current trend is
to use either GEM-nab paclitaxel or FOLFILRINOX based
on the data available for patients with advanced disease
[35, 46, 86, 87] (IIB). Chemotherapy is usually adminis-
tered for 3–4 months followed by assessment of tumor
response. In patients with partial response that allows
surgical resection, it could be a treatment option. In the
remaining patients with partial response and those with
stable disease, chemotherapy treatment as well as consol-
idation with chemotherapy and radiotherapy are valid
options.
The recent data from the LAP007 study (Phase III study
that compared chemoradiotherapy and chemotherapy in
patients with a locally advanced pancreatic cancer con-
trolled after four months of GEM with or without erlotinib)
indicates that there are no survival benefits for chemo-ra-
diation as compared to continuing chemotherapy alone,
although it decreased the risk of local progression and
improved PFS [88] (IA).
It should be noted, however, that this study used con-
ventional external beam radiation and gemcitabine-based
chemotherapy and the results cannot be extrapolated to
those obtained with new chemotherapy regimens and more
modern radiation techniques (IMRT). Data from the
SCALOP trial (Phase II study of induction chemotherapy
followed by GEM or capecitabine-based chemoradiation in
locally advanced pancreatic cancer) suggest that the
radiotherapy combined with fluoropyrimidines achieves
better results than when combined with GEM [89] (IA).
Patients who are candidates for chemotherapy with limi-
tations have a very poor prognosis and should be managed
with either single agent chemotherapy (GEM alone),
combination therapy (GEM ? nab paclitaxel) or radiation
therapy alone (Table 2).
Management of patients with metastatic disease
First line treatment The management of patients with
advanced PDAC is based on systemic chemotherapy. In
those patients who have received prior adjuvant or
neadjuvant treatment, rechallenge should be considered
when the disease-free interval is C6 months. Prior to
treatment initiation, patients should be classified based on
performance status, nutritional status, age and comor-
bidities according to Table 2. For patients able to receive
chemotherapy without limitations, the current standard of
care is either GEM-nab paclitaxel or FOLFIRINOX
[35, 46] (IA). In the lack of randomized studies com-
paring these two regiments no one can be recommended
[90, 91]. FOLFIRINOX should not be administered to
patients [75 years old. In addition, this regimen is
associated with a higher incidence of toxicity and
thromboembolic complications and often requires growth
factor support. FOLFIRINOX should be used with cau-
tion in patients with biliary stents who have increased
risk of biliary tract infections and sepsis. In addition, it is
recommended to administer antiemetic prophylaxis at
least for moderately emetogenic chemotherapy. Patients
who are candidates to chemotherapy with limitations are
best managed with GEM-nab paclitaxel, and should be
administered until progression or unacceptable toxicity;
this is particularly the case for patients with ECOG 2
secondary to high tumor volume in whom tumor reduc-
tion may result in symptomatic improvement (IIB).
Patients with ECOG 2 secondary to comorbidities or
those with severe peripheral neuropathy can be treated
with GEM alone (IIIB). Patients who are not candidates
for chemotherapy should receive palliative treatment.
The optimal management should always be reassessed
and modified if the condition of the patient changes.
Thus, subjects whose condition improves should be
considered for more aggressive approaches. In any group,
enrollment in a clinical trial should always be the pre-
ferred option (Algorithm 2).
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Without limitaons:
ECOG 0-1
Age ≤ 75 years
Bilirubin ≤ 1.5 ULN
Good nutrional status
Lack of comoribidies
GEM + Nab paclitaxel
or
FOLFIRINOX
High Tumor burden: 
Gem + Nab paclitaxel
Commorbidies: 
GEM or GEM + nab paclitaxel
Suitable for chemotherapy
With limitaons:
ECOG 2
Age > 75 years
Mild to moderate neurological or 
endocrine-metabolic organ dysfuncon;
Hyperbilirubinemia > 1.5 x ULN; Cardiac 
dysfuncon; Acute, symptomac, severe 
TED; BMI  < 20 Kg/m2 or >  10% weight loss 
in 3-6 months
Not suitable for chemotherapy
ECOG 3
Severe organ dysfuncons:
Neurologial (severe cognive
impairment), endocrine-
metabolic, infecous
(uncontrolled HIV), renal or
hepac dysfuncon
Supporve treatment
Palliave care
FIRST LINE TREATMENT*
Disease Progression
SECOND LINE TREATMENT*
First line treatment based on GEM (GEM alone or
GEM + nab-paclitaxel
First line treatment based on 5-FU/LV 
(FOLFIRINOX or FOLFOX/XELOX)
Suitable for chemotherapy, 
without liminaons?
Suitable for chemotherapy, 
without liminaons?
First opon:
Nal-IRI + 5-FU/LV**
5-FU/LV (CI) + oxaliplan**
Other opons:
Nab-paclitaxel***
XELOX***
5-FU/LV + Irinotecan***
Capecitabine + Erlonib***
FOLFIRINOX**
Paclitaxel**
If combinaon treatment
is feasible:
Nal-IRI + 5-FU/LV 
5-FU/LV (CI) + 
oxaliplan**
5-FU/LV + Irinotecan
If combinaon treatment
is not feasible:
Nab-paclitaxel***
Capecitabine
5-FU/LV (CI)
Irinotecan
First opon:
GEM + Nab-paclitaxel****
Other opons:
GEM alone****
Depending on limitaons, 
consider:
GEM alone***
GEM + Nab-paclitaxel***
YES YESNO NO
Abbreviaons: GEM: Gemcitabine; XELOX: Capecitabine + oxaliplan; FOLFIRI: 5-FU/LV + Irinotecan; Nal-IRI: Nanoliposomal Irinotecan; 
CI: Connous infusion; *Always consider the inclusion in a clinical trial; **Phase III study; ***PHase II study; ****Retrospecve
In those paents that have received prior adjuvant or neadjuvant treatment rechallenge shouldl be considered when the disease-free 
interval is ≥ 6 months
Algorithm 2. Treatment of metastasc PDAC
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Second line treatment Second line treatment is in gen-
eral recommended after progression to first line treatment
[92] (IA). Treatment decision should be based on the
general status of the patient as well as the first line treat-
ment. For patients who have been treated with GEM based
regimen FOLFOX chemotherapy has demonstrated
improvement in survival as compared to 5-FU in the
CONKO-003 study [93]. These results, however, have not
been confirmed in the PANCREOX trial [94]. More
recently, the NAPOLI-1 showed that MM-398 (liposomal
formulation of irinotecan) in combination with 5-FU/LV is
better than 5-FU/LV alone [95]. For patients who have
received 5-FU/LV based chemotherapy on the first lie sett,
there is very little data to base second line choices. In
general, either GEM alone or GEM combination is rec-
ommended [96].
Treatment monitoring The response to treatment should
be monitored every 8–12 weeks by a CT scan of the chest,
abdomen and pelvis (IIIB). Other imaging modalities such
as MRI and/or PET are not routinely recommended to be
used in a serial basis (IIIB). The tumor marker CA 19.9
should be measured before treatment and every 4–8 weeks
thereafter (IIIB). Tumor progression in patients with rising
CA 19.9 should be confirmed radiologically [7, 35, 46, 97]
(IIIB).
Supportive care
Supportive care aims to improve symptoms, reduce hos-
pital admission and preserve quality of life. Proper symp-
tomatic management is critical to allow administration of
chemotherapy and radiotherapy. Symptomatic manage-
ment should be accomplished in a multidisciplinary fash-
ion. In this section, we will describe the most common
approach to diagnosis and management of the most com-
mon symptoms of PADC.
1. Bile duct obstruction.
Up to 75% of patients with tumors in the head of the
pancreas develop bile duct obstruction which results in
jaundice, itching cholangitis and hepatic dysfunction. If
untreated, hepatic failure may ensure [98]. While surgical
management had been the preferred approach in the past,
particularly coledocoenterostomy, the high mortality of
these techniques together with the excellent results
obtained with endoscopic approaches has resulted in the
preference of endoscopic management [99]. The preferred
approach is endoscopic stent (via ERCP) [100]. Percuta-
neous transhepatic colangiopancreatography with stent
placement is associated with higher risk of infectious
complications and bleeding, being only recommended for
patients in whom the endoscopic approach is not feasible
[101]. Plastic stents have a life span of about four months
and are only recommended for patients with expected short
survival. Patients with longer expected survival should be
treated with metal stents that have a longer functionality
[102]. Surgical management is only recommended for
patients who undergo a laparotomy for other reasons. Bile
duct drainage is clearly recommended in patients who are
scheduled for preoperative chemotherapy, those with
cholangitis, or those in whom surgical resection is expected
to be delayed. However, patients with moderate bilirubin
elevation scheduled to undergo surgery can be safely
operated without drainage [103–105].
2. Duodenal obstruction.
Ten to twenty-five per cent of patients develop duo-
denal obstruction which is associated with severe symp-
toms and deterioration of quality of life. The most
common approach nowadays is the endoscopic placement
of an expansible metallic stent. This approach results in
over 90% success with very few complications. The
preferred surgical treatment is a gastric jejunonostomy
which is only recommended in very selected patients
because of high morbidity and mortality when performed
as a treatment modality [106]. Prophylactic gastroje-
junostomy should be considered in patients with non-re-
sectable tumors who undergo an exploratory laparotomy.
Endoscopic stents are associated with rapid recovery of
oral intake, less morbimortality and a shorter hospital stay
[107, 108]. In contrast, surgical treatment is associated
with better long term outcome. For this reason surgery is
only considered for patients with expected long survival.
All these recommendations achieve a level of evidence
IIB.
3. Pain.
Fifty to sixty per cent of patients with PADC develop
some short of pain. These patients need intensive treat-
ment, with both pharmacological and non-pharmacological
approaches [109]. It is important to consider the precise
cause of the pain, such as for example bowel obstruction,
liver or bone metastasis, or secondary to chemotherapy
(neuropathy, mucositis, enteritis) [110–113]. Table 4
summarizes the most important approaches for pain man-
agement (IIA).
4. Nutritional support.
Malnourishment is very common in patients with PADC
secondary to problems with intake as well as cancer-as-
sociated cachexia. Frequent assessment of nutritional status
is recommended, being Patient-Generated Subjective Glo-
bal Assessment (PG-SGA) the most common scale used in
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oncology [114]. Intervention ranges from dietary counsel-
ing, dietary supplements and enteral feeding. Parenteral
nutrition is only recommended as a temporary approach in
patients with transient inability for enteral feeding with
good general status. For patients scheduled to undergo
surgery who present with severe malnutrition (weight loss
[10% in 6 months, BMI\18.5 kg/m2 and serum albumin
\3 g/dl) it is recommended to provide nutritional support
by dietary supplements, enteral feeding or parenteral
feeding for 7–14 days. More than 50% with PADC have
pancreatic exocrine insufficiency. This problem usually
presents as esteatorrhea. Optimal substitutive treatment
with substitute pancreatic enzymes is recommended
(25,000–150,000 units per meal intake) [115].
Cachexia is a multifactorial syndrome characterized by
permanent loss of lean body mass. It does not respond to
conventional nutritional support and leads to progressive
functional deterioration. 20 to 80% of patients with PADC
have cachexia, being more common in advance disease
[116]. It is a poor prognosis factor and unfortunately, there
is no effective treatment once established. Identification of
patients in a pre-cachexia stage were multimodality
approach may reverse the symptoms is critical [117].
Megestrol acetate and high dose steroids are approved for
this condition. However, in case of megestrol acetate, side
effects such as thrombotic episodes limit its universal
recommendation [118]. All these nutritional support rec-
ommendations achieve a level of evidence of IIB.
5. Thromboembolic disease.
Thromboembolic disease (TED) is one of the most
common complications, with an incidence of 20–35%
[119]. Its etiology is multifactorial, being associated with
poor prognosis, particularly in patients with early throm-
bosis. The risk of TED increase in the perioperative period
in patients with advanced disease and in those treated with
chemotherapy. An elevated D-dymer, poor performance
status, central catheter and absence of prophylaxis increa-
ses the risk. The Khorana index is useful to identify high
risk patients [120]. In randomized clinical trials, prophy-
laxis of deep venous thrombosis (DVT) in patients with
PDAC resulted in significant decrease in the rate of
thrombosis, with no impact on survival [121, 122]. Routine
prophylaxis of thrombosis is not recommended in the
ambulatory setting [123] (IA). In patients with a Khorana
index C3 and no risk of bleeding, prophylaxis with low
Table 4 Pain management strategies (IIA)
Mild pain NSAIDs: Taking into account maximum doses and side effects (gastrointestinal bleeding, nephrotoxicity [110]
acetaminophen
Moderate/severe pain Opioids: any opioid as first choice, except for methadone (secondary choice). Methadone has great benefit in
neuropathic pain due to its anti NMDA effect. Should be administered by trained personnel
Other treatments
Adjuvant treatment/co-
analgesics
Corticosteroids
Gabapentine (if neuropathic pain)
Intrathecal catheters To manage moderate to severe pain
Lower frequency of secondary adverse events, with better pain control [111]
First choice: hydromorphone, ziconotide, local anesthetic
Severe neuropathic pain: baclofen, clonidine
Miscellaneous (little
evidence)
Other therapies: phentolamine, capsaicin, cryoablation, acupuncture
Radiotherapy Indicated for management of refractory pain, especially in patients with good performance status and localized
pain caused by isolated metastases or pancreas and adjacent structures involvement
Celiac plexus block [112] Provides better analgesic control (benefit in[80% of the patients) and/or decreases the opioid dose when
compared to standard analgesic treatment
Cause a disruption in the pain signaling by an average of 3 months
It can be performed via percutaneous under ultrasound control, surgical or endoscopic by ultrasound. In terms of
technique, there isn’t enough evidence to make any recommendations Side effects are rare (transient
hypotension, constipation or diarrhea)
There is no evidence to recommend the timing for the blockage (early, at diagnosis, or late when there is poor pain
control)
There is no evidence that increases survival
In the clinical practice celiac plexus block is reserved for patients with poor pain control despite escalation with
opioids or for those with opioid related secondary adverse events [113]
There are limited data regarding the repeated use of celiac plexus block (pain relief is achieved in 29% of the
patients)
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molecular weight heparin could be considered (IIB).
Hospitalized patients and those who underwent surgery
treatment with low molecular weight heparin are recom-
mended for at least 6 months (IIA).
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